MARTINSRIED/MUNICH; Germany; April 28 /PRNewswire-FirstCall/ -- U.S.
Research and Development Facilities in Waltham/Boston; Mass. and Princeton;
N.J. -- Biotech AG (Frankfurt Stock Exchange: GPC; TecDAX index; Nasdaq: GPCB)
today announced that the Company will be presenting at the Rodman & Renshaw
Techvest 2nd Annual Global Healthcare Conference in Paris, France.
The presentation will be given by Mirko Scherer, Ph.D., Chief Financial
Officer of the Company, and is scheduled for Thursday, May 5, 2005 at 14:50
CET/8:50 AM EDT. The presentation will be webcast live and will be accessible
through the GPC Biotech Web site at http://www.gpc-biotech.com. A replay will
be available via the Web site following the live event.
GPC Biotech AG is a biopharmaceutical company discovering and developing
new anticancer drugs. The Company's lead product candidate -- satraplatin --
is currently in a Phase 3 registrational trial as a second-line chemotherapy
treatment in hormone-refractory prostate cancer following successful
completion of a Special Protocol Assessment by the U.S. FDA and receipt of a
Scientific Advice letter from the European central regulatory authority, EMEA.
The FDA has also granted fast track designation to satraplatin for this
indication. Satraplatin was in-licensed from Spectrum Pharmaceuticals, Inc.
Other anticancer programs include: a monoclonal antibody with a novel
mechanism-of-action against a variety of lymphoid tumors, currently in Phase 1
clinical development, and a small molecule broad-spectrum cell cycle
inhibitor, currently in pre-clinical development. The Company is leveraging
its drug discovery technologies to elucidate the mechanisms-of-action of drug
candidates and to support the growth of its drug pipeline. GPC Biotech also
has a multi-year alliance with ALTANA Pharma AG working with the ALTANA
Research Institute in the U.S., which provides GPC Biotech with revenues
through mid-2007. GPC Biotech AG is headquartered in Martinsried/Munich
(Germany). The Company's wholly owned U.S. subsidiary has research and
development sites in Waltham, Massachusetts and Princeton, New Jersey. For
additional information, please visit the Company's Web site at http://www.gpc-
biotech.com.
For further information, please contact:
GPC Biotech AG Fraunhoferstr.
20 82152 Martinsried/Munich, Germany
Phone/Fax: +49 (0)89 8565-2600/-2610
info@gpc-biotech.com
Martin Braendle (ext. 2693)
Associate Director, Investor Relations &Corporate Communications
martin.braendle@gpc-biotech.com
In the U.S.:
Laurie Doyle
Associate Director, Investor Relations &
Corporate Communications
Phone: +1 781 890 9007 X267
laurie.doyle@gpc-biotech.com
SOURCE GPC Biotech AG
 back to top
Related links:
http://www.gpc-biotech.com
CONTACT:
Martin Braendle, Associate Director, Investor
Relations & Corporate Communications, +49 (0)89 8565-2600 ext.
2693, martin.braendle@gpc-biotech.com, or In the U.S., Laurie
Doyle, Associate Director, Investor Relations & Corporate
Communications, +1-781-890-9007 ext. 267,
laurie.doyle@gpc-biotech.com
|
